Adakveo® (crizanlizumab-tmca)

Adakveo (crizanlizumab‑tmca) is covered to reduce vaso‑occlusive crises in patients with sickle cell disease aged ≥16 years per the FDA indication, and use outside this FDA‑approved indication is not supported. Coverage requires documented age ≥16, ≥1 sickle cell‑related crisis in the prior 12 months for initial approval, appropriate hydroxyurea status (on hydroxyurea, intolerant/inadequate response, or not a candidate), prescription or consult with a sickle‑cell specialist, adherence to the 5 mg/kg IV dosing schedule (Week 0, Week 2, then every 4 weeks), approvals limited to 12 months, and documented clinical benefit for re‑authorization.

"Age restriction: Patient must be 16 years of age or older."

Sign up to see full coverage criteria, indications, and limitations.